Ray Therapeutics, Inc. — Form D
Ray Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-05-26. The offering totals $100.0M, of which $14.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-05-26
- Form: D
- Accession: 0001920476-23-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $100.0M
- Amount sold: $14.0M
- Remaining: $86.0M
- Investors: 13
- Date of first sale: 2023-05-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-482772
Issuer
- Name: Ray Therapeutics, Inc.
- CIK: 0001920476
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: ONE SANSOME STREET, SUITE 3500, SAN FRANCISCO, CA, 94104
- Phone: 858-617-8610
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Gary Abrams | Director | SAN FRANCISCO, CA |
| Sean Ainsworth | Director | Farmington Hills, MI |
| Tiba Aynechi | Director | South San Francisco, CA |
| Paul Bresge | Director | Newport Beach, CA |
| Raymond Camahort | Director | Boston, MA |
| Hannah Chang | Director | Cary, NC |
| Dmitry Kuzmin | Director | St Peter Port, Y7 |
| Sean Ainsworth | Executive Officer | Farmington Hills, MI |
| Paul Bresge | Executive Officer | Newport Beach, CA |
| Andrew Howard | Executive Officer | Athens, GA |
| Cameron Gallagher | Director | San Diego, CA |
Other filings by this issuer (1)
More